Price Chart
Key Statistics
Previous Close
$30.85Day Range
52-Week Range
Avg Volume
26.2KDividend Yield
1.27%Expense Ratio
0.59%AUM
$47.5MShares Outstanding
1.3METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 50.39% |
| Denmark | 19.50% |
| China | 11.07% |
| Japan | 5.42% |
| South Korea | 4.00% |
| United Kingdom | 3.31% |
| Switzerland | 2.87% |
| Hong Kong | 2.32% |
| Singapore | 0.77% |
| Other | 0.34% |
Fund Information
- Issuer
- Roundhill Investments
- Category
- Healthcare
- Types
- Pharma
- Inception Date
- May 21, 2024
- Exchange
- NASDAQ
- Description
- Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.
Similar ETFs
The Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund issued by Roundhill Investments that launched on May 21, 2024. It currently manages $47.5M in assets under management. The fund charges an expense ratio of 0.59%. The fund holds 29 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 67.3% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | 18.87% | 8,247 | $9.3M |
| 2 | NVO | Novo Nordisk A/S | 12.85% | 144,433 | $6.3M |
| 3 | PFE | Pfizer Inc | 6.40% | 122,599 | $3.1M |
| 4 | VKTX | Viking Therapeutics Inc | 4.45% | 73,536 | $2.2M |
| 5 | 1093.HK | CSPC Pharmaceutical Group Ltd | 4.43% | 2,360,000 | $2.2M |
| 6 | ZEAL.CO | Zealand Pharma A/S | 4.23% | 40,944 | $2.1M |
| 7 | 4519.T | Chugai Pharmaceutical Co Ltd | 4.16% | 43,300 | $2.0M |
| 8 | KLRA | Kailera Therapeutics Inc | 4.14% | 96,982 | $2.0M |
| 9 | 128940.KS | Hanmi Pharm Co Ltd | 4.03% | 6,165 | $2.0M |
| 10 | 1801.HK | Innovent Biologics Inc | 3.74% | 188,500 | $1.8M |
| 11 | AMGN | Amgen Inc | 3.70% | 5,269 | $1.8M |
| 12 | AZN | AstraZeneca PLC | 3.28% | 8,878 | $1.6M |
| 13 | ROP.SW | Roche Holding AG | 2.86% | 3,413 | $1.4M |
| 14 | GPCR | Structure Therapeutics Inc | 2.60% | 32,719 | $1.3M |
| 15 | REGN | Regeneron Pharmaceuticals Inc | 2.56% | 2,001 | $1.3M |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | -0.24% | |
| 1W | -0.42% | |
| 1M | -3.26% | |
| 3M | -2.97% | |
| 6M | -11.30% | |
| YTD | -10.36% | |
| 1Y | +11.16% | |
| 3Y | +21.32% | |
| 5Y | +21.32% |
Moving Averages
$30.74
Above 20-Day MA$31.22
Below 50-Day MA$31.17
Below 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$37.01
Current Price
$30.78
52-Week Low
$23.47
Current Yield
1.27%
Annual Dividend
$0.4630
Frequency
1x/year
Last Ex-Date
Dec 30, 2025
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.4099 | Dec 31, 2025 |
| Dec 30, 2024 | $0.0531 | Dec 31, 2024 |
Dividend Payments Over Time
Category Comparison
| Metric | OZEM | Healthcare(174 ETFs) | Pharma(29 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.59% | 0.60% | 0.66% |
| AUM | $47.5M | $875.8M | $1.45B |
| Dividend Yield | 1.27% | 3.42% | 1.82% |
| Avg Volume | 26.2K | 270.2K | 508.2K |
| Holdings | 29 | 89 | 42 |
| Performance | |||
| 1-Month Return | -2.69% | +2.02% | +2.81% |
| 6-Month Return | -7.40% | +3.84% | +5.39% |
| YTD Return | -9.67% | +3.23% | +4.76% |
| 1-Year Return | +12.36% | +23.91% | +34.52% |
Compare with Another ETF
Search for an ETF to compare with OZEM:
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.